Cogent Biosciences, Inc. - stock earnings
COGT Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -54.4 million USD | ? USD |
| 2023Q3 | -55.4 million USD | ? USD |
| 2023Q2 | -44.1 million USD | ? USD |
| 2023Q1 | -33.9 million USD | ? USD |
| 2022Q4 | -35.5 million USD | ? USD |
| 2022Q3 | -33.3 million USD | ? USD |
| 2022Q2 | -34.0 million USD | ? USD |
| 2022Q1 | -29.9 million USD | ? USD |
| 2021Q4 | -24.9 million USD | ? USD |
| 2021Q3 | -19.1 million USD | ? USD |
| 2021Q2 | -16.5 million USD | ? USD |
| 2021Q1 | -11.7 million USD | ? USD |
| 2020Q4 | -11.3 million USD | ? USD |
| 2020Q3 | -50.0 million USD | 312000 USD |
| 2020Q2 | -7.4 million USD | 528000 USD |
| 2020Q1 | -6.1 million USD | 7.0 million USD |
| 2019Q4 | 2.3 million USD | 15.3 million USD |
| 2019Q3 | -11.9 million USD | 1.0 million USD |
| 2019Q2 | -10.5 million USD | 3.1 million USD |
| 2019Q1 | -11.7 million USD | 3.1 million USD |
| 2018Q4 | -8.6 million USD | 3.8 million USD |
| 2018Q3 | -10.2 million USD | 2.0 million USD |
| 2018Q2 | -9.0 million USD | 1.7 million USD |
| 2018Q1 | -6.7 million USD | 2.2 million USD |
| 2017Q4 | -6.7 million USD | 2.1 million USD |
| 2017Q3 | -7.0 million USD | 2.3 million USD |
| 2017Q2 | -5.9 million USD | 2.1 million USD |
| 2017Q1 | -5.9 million USD | 1.8 million USD |
COGT Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -192.4 million USD | ? USD |
| 2022 | -132.6 million USD | ? USD |
| 2021 | -71.8 million USD | ? USD |
| 2020 | -66.5 million USD | 7.9 million USD |
| 2019 | -30.3 million USD | 22.5 million USD |
| 2018 | -34.5 million USD | 9.7 million USD |
| 2017 | -25.5 million USD | 8.4 million USD |
| 2016 | -18.1 million USD | 6.4 million USD |
| 2015 | -6.6 million USD | 3.0 million USD |
COGT
Price: $7.53
52 week price:
Earnings Per Share: -2.42 USD
P/E Ratio: -2.44
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 528500
Ebitda: -29.7 millionMarket Capitalization: 726.4 million